The most important number in Vancouver’s venture ecosystem right now isn't a funding round size or a valuation. It’s 47.

That is the number of spin-out companies recorded by UBC’s University-Industry Liaison Office in fiscal 2025—a record and a 52 per cent increase from the 31 spin-outs formed in fiscal 2023. For a city that has long watched its best university science commercialized elsewhere, this pipeline shift is structural, not cyclical.

It is arriving at the right moment.

The Supply Side

BC’s venture capital community has spent the past 18 months debating deployment strategy—which sectors to back, how to price early-stage deals, and whether AI-adjacent bets justify compressed timelines. Less attention has been paid to the quality of the output from the province’s research institutions.

University spin-outs differ from accelerator graduates. They typically enter the market with defensible intellectual property, federal research funding, and founders who have spent years on a single technical problem. The failure modes and upside profiles differ accordingly.

Studies comparing spin-out performance against accelerator cohorts consistently show higher exit multiples and stronger IP defensibility among university-originated companies, particularly in deep tech, life sciences, and cleantech—sectors where BC institutions hold global standing.

Three factors are driving UBC’s surge. First, the UILO introduced pre-seed bridge funding that allows founders to begin building before securing external capital. Second, IP licensing terms were streamlined, reducing the negotiation friction that once added months to formation timelines. Third, a cohort of faculty founders who completed successful prior exits are now mentoring colleagues, creating a compounding peer-to-peer commercialization culture.

SFU Momentum

SFU’s Innovate program is posting similar momentum, with a pipeline expanding across health tech, sustainable materials, and applied AI. Together, these institutions represent a shift in the volume and quality of early-stage companies entering the BC market.

Federal funding is accelerating this trend. NSERC Alliance grants flowing to UBC and SFU in 2025–26 are creating co-investment structures that de-risk early IP development. For investors, this means less capital spent proving scientific feasibility and more runway allocated to market development.

Genome BC’s commercialization data indicates that BC’s life sciences spin-out activity is increasingly tied to university IP pipelines, suggesting institutional infrastructure is becoming the dominant source of new company creation in that sector.

Investor Outlook

As noted previously, BC venture funds are sitting on significant dry powder and are seeking opportunities that justify expected risk-return profiles. Historically, university spin-outs offered the right profile but lacked volume. At 47 formations per year from UBC alone, that calculus is changing. Combined with SFU’s output and the broader BC tech ecosystem’s expanding institutional base, investors can begin treating university spin-outs as a primary dealflow channel.

Several Vancouver-based early-stage funds have deepened their relationships with the UILO over the past 24 months to secure early access to formations. This suggests the pipeline has reached critical mass.

The Bigger Picture

BC has long contended with the tendency for the province’s best science to be commercialized in California or Massachusetts. While this surge does not solve the challenges of housing costs, talent competition, or a thin late-stage capital market, it indicates that more researchers are choosing to build locally.

If the venture community meets this supply with serious capital and support—including networks, customers, and follow-on capacity—the conversion rate from spin-out to scaled BC company may finally shift. The pipeline is open; the question is whether investors are ready to run it.